https://www.selleckchem.com/products/ly2606368.html Five percent do not perform daily QC; all analyzed external QC at least once per month. When QC limits exceed acceptable limits, 92% stop testing. Expired materials were used by 5%. The majority collected data for quality improvements. Eleven percent thought their organization's POCT is acceptable. The majority of respondents believe improvements need to be made in POCT. Conclusions Analysts' POCT practices have and are improving to contribute positively to patients' healthcare and safety. Analysts do recognize problems and their wants/needs provide important information to improve their practices. Most participants desire more in-house and/or manufacturer training, explicit directions from manufacturers, manufacturer built-in quality and function checks, and oversight.Background There is a well-documented lack of rapid, low-cost tuberculosis (TB) drug resistance diagnostics in low-income settings across the globe. It is these areas that are plagued with a disproportionately high disease burden and in greatest need of these diagnostics. Methods In this study, we compared the performance of Light Forge, a microfluidic high-resolution melting analysis (HRMA) prototype for rapid low-cost detection of TB drug resistance with a commercial HRMA device, a predictive "nearest-neighbor" thermodynamic model, DNA sequencing, and phenotypic drug susceptibility testing (DST). The initial development and assessment of the Light Forge assay was performed with 7 phenotypically drug resistant strains of Mycobacterium tuberculosis (M.tb) that had their rpoB gene subsequently sequenced to confirm resistance to Rifampin. These isolates of M.tb were then compared against a drug-susceptible standard, H37Rv. Seven strains of M.tb were isolated from clinical specimens and individually analyzed to characterize the unique melting profile of each strain. Results Light Forge was able to detect drug-resistance linked mutations with 100% concor